Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling
Authors:
- 9 June 2022
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (7) , 518-528
Abstract
Purpose: Medication adherence to concomitant oral antidiabetics, statins, and renin‐angiotensin system (RAS) antagonists (triple therapy) is vital to manage glycated hemoglobin (A1C) and low‐density lipoprotein cholesterol (LDL‐C) control among patients with comorbid diabetes, hyperlipidemia, and hypertension. The objective of the current study was to evaluate the association between adherence to concomitant triple therapy and A1C as well as LDL‐C outcomes, among elderly patients using marginal structural modeling.Methods: A retrospective cohort study with patients on concurrent triple therapy was conducted using a Texas Medicare Advantage database from January 2016 until December 2019. Medication adherence to concurrent triple therapy was measured every 6 months using proportion of days covered (PDC) to determine the different adherence groups. A1C and LDL‐C control was also measured every 6 months. A marginal structural model controlling for baseline covariates and time‐varying confounders affected by prior adherence was conducted to evaluate the association between adherence to concomitant triple therapy and A1C and LDL‐C control.Results: The LDL‐C cohort was comprised of 4803 patients and the A1C cohort was comprised of 5314 patients on triple therapy. Patients who were adherent to triple therapy [odds ratio(OR):1.84, 95% confidence interval (CI): 1.62–2.10] and adherent to double therapy (OR:1.42, 95% CI: 1.24–1.62) were more likely to have their LDL‐C in control as compared to patient's adherent to monotherapy/none. Similarly, patients who were adherent to triple therapy (OR:1.30, 95% CI: 1.11–1.52) and adherent to double therapy (OR:1.32, 95% CI: 1.12–1.55) were more likely to have their A1C in control as compared to patient's adherent to monotherapy/none.Conclusion: The current study demonstrated the beneficial effects of adherence to concurrent oral antidiabetics, statins, and RAS antagonists among elderly patients in a real‐world setting.Keywords
This publication has 39 references indexed in Scilit:
- Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failurePharmacoepidemiology and Drug Safety, 2011
- Estimating the Effect of Medication Adherence on Health Outcomes among Patients with Type 2 Diabetes—An Application of Marginal Structural ModelsValue in Health, 2010
- Estimating Antihypertensive Effects of Combination Therapy in an Observational Study Using Marginal Structural ModelsBiometrical Journal, 2009
- Does Synchronizing Initiation of Therapy Affect Adherence to Concomitant Use of Antihypertensive and Lipid-Lowering Therapy?American Journal of Therapeutics, 2009
- Trends in adherence to secondary prevention medications in elderly post‐myocardial infarction patientsPharmacoepidemiology and Drug Safety, 2008
- Traditional versus marginal structural models to estimate the effectiveness of β‐blocker use on mortality after myocardial infarctionPharmacoepidemiology and Drug Safety, 2008
- Predictors of Adherence to Concomitant Antihypertensive and Lipid-Lowering Medications in Older AdultsDrugs & Aging, 2008
- Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 DiabetesHypertension, 2005
- Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive PatientsCirculation, 2004
- Adherence to Long-Term Therapies: Evidence for ActionEuropean Journal of Cardiovascular Nursing, 2003